OMALIZUMAB

Brand name:

• Xolair®

Pharmaceutical company:

NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED

Condition/indication:
(therapeutic use)

• Chronic rhinosinusitis with nasal polyps (CRSwNP)

PBAC Submission type:

Change to existing listing (Category 2)

Comment:

--

Public Summary Document:

Not yet available

Related medicines:

--

Submission received for:

May 2025 PBAC meeting

Opportunity for consumer comment:

Open 30/01/2025 and close 26/03/2025 (see PBS Website)

PBAC meeting:

Held on 09/05/2025

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

Awaiting lodgement from pharmaceutical company

5Lodgement of required documentation:

6Agreement to listing arrangements:

Has not yet commenced

7Government processes:

Has not yet commenced

8Medicine listed on the PBS:

Has not yet occurred

---